Tonix to Present at 6th Fibromyalgia Congress

Tonix Pharmaceuticals, a biopharmaceutical firm, is set to showcase further findings from its Phase 3 RESILIENT trial at the 6th International Congress on Controversies in Fibromyalgia, taking place in Brussels on March 7, 2024. The trial pertains to the efficacy of Tonmya™, the company's fibromyalgia management drug candidate, which has already demonstrated positive outcomes in two separate Phase 3 studies.

The company, which has a robust pipeline of CNS disorder treatments, is aiming to submit a New Drug Application for Tonmya to the FDA in 2024. In addition to fibromyalgia, the drug is also being considered for treating acute stress reactions and fibromyalgia-type Long COVID. Tonix's portfolio is diverse, featuring a biologic designed to counter cocaine intoxication, TNX-1300, and a monoclonal antibody, TNX-1500, intended for preventing organ transplant rejection and treating autoimmune diseases.

Tonix's commercial arm, Tonix Medicines, currently markets Zembrace® SymTouch® and Tosymra®, treatments for acute migraines in adults. The company is also exploring rare diseases and infectious diseases with its product candidates.

While the company's drug candidates are still under investigation and have not received regulatory approval, Tonix remains committed to advancing its research and development efforts. The upcoming presentation in Brussels will provide an opportunity to share more insights into the progress and potential impact of its fibromyalgia treatment.

It is important to note that the development and approval process for new pharmaceuticals is complex and subject to numerous risks and uncertainties. Tonix is aware of these challenges and continues to navigate the regulatory landscape with the goal of bringing new treatments to market.